|
Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Mylan; Puma Biotechnology; Samsung Bioepis |
Consulting or Advisory Role - Napo Pharmaceuticals |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Genentech (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Sermonix Pharmaceuticals (Inst) |
|
|
Honoraria - Athenex; bioTheranostics; natera; OncoCyte |
Consulting or Advisory Role - Almac Diagnostics; AstraZeneca; Bristol Myers Squibb; Clovis Oncology; Eisai; H3 Biomedicine; Immunomedics; Merck; Novartis; Pfizer; Roche/Genentech; Seagen; Syndax |
Research Funding - AstraZeneca (Inst); Bristol Myers Squibb (Inst); Genentech (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
(OPTIONAL) Uncompensated Relationships - Foundation Medicine; NanoString Technologies |
|
|
No Relationships to Disclose |
|
|
Honoraria - bioTheranostics; sanofi |
Consulting or Advisory Role - Novartis; Seagen |
Research Funding - Amgen (Inst); Merck (Inst); Puma Biotechnology (Inst); Seagen (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Berry Consultants |
|
|
|
Stock and Other Ownership Interests - Agendia |
|
|
Honoraria - Boehringer Ingelheim |
Consulting or Advisory Role - Martell diagnostic |
Research Funding - Boehringer Ingelheim |
|
|
Research Funding - Calithera Biosciences (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Consulting or Advisory Role - Blue Cross Blue Shield Association |
|
Travel, Accommodations, Expenses - Blue Cross Blue Shield Association |
(OPTIONAL) Uncompensated Relationships - Quantum Leap Healthcare Collaborative |